Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry.
The term refers to some of the biggest pharmaceutical groups in the world, viewed particularly influential as a group. To provide a feel of their sheer size, the market cap of the top 10 Big Pharma companies is $1.7 trillion—Johnson & Johnson being the largest, with a market capitalization of $374 billion.
So far, Big Pharma has watched the hashish enterprise from the sidelines, deterred with the aid of regulatory concerns. What we are seeing now is the sound asleep giant’s takeover slowly intensifying as more patents, partnerships, and subsidized clinical trials come to fruition.
The cannabis plant has been used in medication for 6,000 years. However, there is still sizeable debate around the position it plays in healthcare today. There are presently nearly 400 active and completed clinical trials worldwide surrounding cannabidiol (CBD), a type of cannabinoid that makes up 40% of the hashish plant’s extract.
Source: www.visualcapitalist.com
0 Comments